Su Hanyang, Wang Jie, Cao Xinyu, Zhang Xiangqian, Zhang Huajun, Liu Xiaojin
Department of Respiratory Medicine & Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, China.
Department of Physiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
Sci Rep. 2025 Aug 7;15(1):28942. doi: 10.1038/s41598-025-11836-8.
Integrin αV (ITGAV) plays a key role in cell adhesion, migration, and immune regulation, and is implicated in tumor progression. However, its comprehensive expression profile and functional relevance across different cancers remain poorly understood. We conducted an integrative pan-cancer analysis of ITGAV using data from TCGA, GTEx, CCLE, and other public databases. Expression, diagnostic value (via ROC analysis), and prognostic significance (via Cox and Kaplan-Meier analyses of OS, DSS, PFS, and DFS) were assessed. We further explored ITGAV's correlation with immune cell infiltration and immune-related genes, its predictive role in immunotherapy response based on immunophenoscore (IPS), and its drug-binding potential through molecular docking. (1) ITGAV was significantly overexpressed in multiple cancer types including LIHC, COAD, and STAD. (2) ROC analysis confirmed its strong diagnostic value, particularly in HNSC, UCEC, and ESCA. (3) High ITGAV expression was associated with poorer survival outcomes in most cancers, while a protective role was observed in KIRC. (4) ITGAV expression was positively correlated with immune cell infiltration and co-expressed with immune-activating and immunosuppressive genes. (5) The expression level of ITGAV correlates with the IPS score, suggesting its predictive value for the benefit of immunotherapy. (6) Molecular docking identified strong binding affinities between ITGAV and six candidate compounds, including gemcitabine and pioglitazone. Our findings demonstrate that ITGAV is a promising biomarker for diagnosis, prognosis, and immunotherapy prediction across cancers. Its immunological associations and druggability highlight its potential as a candidate therapeutic target.
整合素αV（ITGAV）在细胞黏附、迁移和免疫调节中起关键作用，并与肿瘤进展有关。然而，其在不同癌症中的综合表达谱和功能相关性仍知之甚少。我们使用来自TCGA、GTEx、CCLE和其他公共数据库的数据对ITGAV进行了综合泛癌分析。评估了其表达、诊断价值（通过ROC分析）和预后意义（通过对总生存期、疾病特异性生存期、无进展生存期和疾病无进展生存期进行Cox和Kaplan-Meier分析）。我们进一步探讨了ITGAV与免疫细胞浸润和免疫相关基因的相关性、基于免疫表型评分（IPS）在免疫治疗反应中的预测作用以及通过分子对接分析其药物结合潜力。（1）ITGAV在包括肝癌（LIHC）、结肠癌（COAD）和胃癌（STAD）在内的多种癌症类型中显著过表达。（2）ROC分析证实了其强大的诊断价值，尤其是在头颈部鳞状细胞癌（HNSC）、子宫内膜癌（UCEC）和食管癌（ESCA）中。（3）在大多数癌症中，ITGAV高表达与较差的生存结果相关，而在肾透明细胞癌（KIRC）中观察到其具有保护作用。（4）ITGAV表达与免疫细胞浸润呈正相关，并与免疫激活和免疫抑制基因共表达。（5）ITGAV的表达水平与IPS评分相关，表明其对免疫治疗获益具有预测价值。（6）分子对接确定了ITGAV与六种候选化合物之间具有强结合亲和力，包括吉西他滨和吡格列酮。我们的研究结果表明，ITGAV是一种有前景的跨癌症诊断、预后和免疫治疗预测生物标志物。其免疫学关联和可成药性突出了其作为候选治疗靶点的潜力。
